Welcome to our dedicated page for Anaptysbio news (Ticker: ANAB), a resource for investors and traders seeking the latest updates and insights on Anaptysbio stock.
AnaptysBio, Inc. (Nasdaq: ANAB) generates a steady flow of news as a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. News coverage on this page centers on its internal pipeline, royalty-bearing collaborations, corporate strategy and legal developments.
Investors following ANAB news will see updates on rosnilimab, a pathogenic T cell depleter that has completed a Phase 2b trial in rheumatoid arthritis and has been evaluated in ulcerative colitis, as well as early-stage programs ANB033 and ANB101. Company announcements describe clinical data readouts, safety and efficacy findings, and decisions to advance or discontinue specific trials, such as the discontinuation of a Phase 2 ulcerative colitis study after not meeting primary and key secondary endpoints at Week 12.
Another key news theme is AnaptysBio’s financial collaborations. Releases detail royalty and milestone expectations from Jemperli (dostarlimab-gxly), the PD-1 antagonist licensed to GSK through Tesaro, and from imsidolimab, the IL-36 receptor antagonist licensed to Vanda Pharmaceuticals. Updates from partners, such as Vanda’s Biologics License Application submission for imsidolimab, also feature prominently because AnaptysBio holds the underlying license.
Corporate and capital allocation developments appear in ANAB news as well, including the company’s intent to separate its biopharma operations from its substantial royalty assets by the end of 2026 and board-authorized stock repurchase plans. Legal and regulatory items, such as AnaptysBio’s litigation with Tesaro and GSK over the Jemperli collaboration and related SEC Form 8-K filings, also contribute to the news flow. This page aggregates these announcements so readers can track how clinical results, royalty assets, strategic separation plans and legal proceedings may shape AnaptysBio’s trajectory over time.
Anaptys (Nasdaq: ANAB) announced that its CEO Daniel Faga and other executives will participate in multiple investor conferences in February–March 2026, including Guggenheim, Piper Sandler, TD Cowen, Barclays, UBS, and Leerink.
Live fireside chats and 1x1 meetings are scheduled; webcasts will be available on the company's investor website with replays for at least 30 days.
Summary not available.
Anaptys (Nasdaq: ANAB) announced that Daniel Faga, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan 13, 2026 at 4:30pm PT / 7:30pm ET.
A live webcast will be available on the company's investor site at https://ir.anaptysbio.com/presentations-and-events, with a replay available for at least 30 days after the event.
Vanda Pharmaceuticals (Nasdaq: VNDA) submitted a Biologics License Application (BLA) to the FDA on Dec 15, 2025 for imsidolimab to treat generalized pustular psoriasis (GPP).
The BLA is supported by positive global Phase 3 GEMINI-1 and GEMINI-2 results: a single intravenous dose produced rapid clearance (clear or almost clear skin) with efficacy maintained during an approximately 2-year maintenance period with monthly dosing, and a favorable safety profile with no clinically meaningful safety signals reported. Vanda requested priority review, which could enable FDA action as early as mid-2026 if granted.
Anaptys (Nasdaq: ANAB) said CEO Daniel Faga and other executives will participate in multiple December investor conferences, including a fireside chat and 1x1 meetings at the Piper Sandler 37th Annual Healthcare Conference in New York on Dec 2, 2025 at 1:30 PM ET and the Evercore 8th Annual Healthcare Conference in Coral Gables on Dec 3, 2025 at 7:55 AM ET.
Live webcasts of the fireside chats will be available on the company investor website and replays will be available for at least 30 days after each event.
Anaptys (Nasdaq: ANAB) announced an amended $100.0 million stock repurchase plan, in addition to $6.4 million remaining under the prior $75.0 million plan.
The company previously repurchased 3,443,188 shares, equal to 11.2% of shares outstanding before that repurchase program. Purchases may occur in open market transactions or under Rule 10b5-1/10b-18 programs.
Anaptys expects to end 2025 with approximately $300 million in cash, cash equivalents and investments, which includes an anticipated one-time $75 million commercial sales milestone from GSK tied to Jemperli reaching $1 billion in worldwide net sales. The repurchase plan expires March 31, 2026 and may be suspended or discontinued at any time; it does not obligate any repurchases.
Summary not available.
Anaptys (Nasdaq: ANAB) reported that its Phase 2 trial of rosnilimab in moderate-to-severe ulcerative colitis did not meet the Week 12 primary endpoint (mean change in modified Mayo Score) or key secondary endpoints of clinical response and remission; the UC trial will be discontinued.
Rosnilimab was well tolerated with no new safety signals and showed ~90% depletion of pathogenic T cells in blood and PD-1+ T cell depletion in colon at Week 12. Discontinuing UC will save at least $10 million. Company expects to end 2025 with approximately $300 million, including a one-time $75 million GSK milestone in Q4 2025 tied to Jemperli sales, and plans to pursue rosnilimab in RA with an H1 2026 update and to separate biopharma operations from royalty assets in 2026.
Anaptys (NASDAQ: ANAB) said CEO Daniel Faga and other executives will participate in multiple investor conferences in November 2025, including TD Cowen Immunology & Inflammation Summit (virtual) on Nov 12, 2025 at 8:00 AM ET, Guggenheim Healthcare Innovation Conference (Boston) on Nov 12, 2025 at 11:30 AM ET, Stifel Healthcare Conference (New York) on Nov 13, 2025 at 1:20 PM ET, and Jefferies Global Healthcare Conference (London) on Nov 17, 2025 at 4:00 PM GMT.
Live webcasts and replays (available for at least 30 days) will be posted on Anaptys’ investor presentations and events page.
Anaptys (Nasdaq: ANAB) reported Q3 2025 results and announced intent to separate its biopharma operations from its royalty management business by year-end 2026 to unlock value across two public companies. The company expects to accrue a one-time $75 million commercial milestone in Q4 2025 when GSK's Jemperli reaches $1 billion in worldwide sales and cites >$390 million in annualized royalties at GSK peak-sales guidance of >$2.7 billion.
Operationally, Anaptys highlighted rosnilimab Phase 2b RA data and expects top-line Week-12 UC Phase 2 data in Nov/Dec 2025; ANB033 Phase 1b in celiac initiated with data expected in Q4 2026. Cash and investments were $256.7 million at Sept 30, 2025, with ~3.34M shares repurchased (~10.9% outstanding) for $65.2 million.
FAQ
What is the current stock price of Anaptysbio (ANAB)?
What is the market cap of Anaptysbio (ANAB)?
